Terms: = Prostate cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
566 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract] [Full Text] [Related]
3. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression.
Angappulige DH; Mahajan NP; Mahajan K
Trends Cancer; 2024 Apr; 10(4):369-381. PubMed ID: 38341319
[TBL] [Abstract] [Full Text] [Related]
5. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
6. A Bayesian fine-mapping model using a continuous global-local shrinkage prior with applications in prostate cancer analysis.
Li X; Sham PC; Zhang YD
Am J Hum Genet; 2024 Feb; 111(2):213-226. PubMed ID: 38171363
[TBL] [Abstract] [Full Text] [Related]
7. ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
Jing N; Zhang K; Chen X; Liu K; Wang J; Xiao L; Zhang W; Ma P; Xu P; Cheng C; Wang D; Zhao H; He Y; Ji Z; Xin Z; Sun Y; Zhang Y; Bao W; Gong Y; Fan L; Ji Y; Zhuang G; Wang Q; Dong B; Zhang P; Xue W; Gao WQ; Zhu HH
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099497
[TBL] [Abstract] [Full Text] [Related]
8. CAV1 and KRT5 are potential targets for prostate cancer.
Guo L; Liu Y; Yang T; Wang G; Liu J; Li S; Liu B; Cai J
Medicine (Baltimore); 2023 Dec; 102(49):e36473. PubMed ID: 38065913
[TBL] [Abstract] [Full Text] [Related]
9. Chemical Characterization, DNA-Damage Protection, Antiproliferative Activity and in Silico Studies of the Essential Oils from Perralderia coronopifolia Coss.
Boussaha S; Lassed S; Abdelwahab AB; Krid A; Altun M; Chalard PP; Chalchat PJC; Figueredo G; Zama PD; Demirtas PI; Benayache PS; Benayache PF
Chem Biodivers; 2024 Feb; 21(2):e202301535. PubMed ID: 38010960
[TBL] [Abstract] [Full Text] [Related]
10. A novel intronic circular RNA circfgfr1
Wang R; Zhong J; Pan X; Su Z; Xu Y; Zhang M; Chen X; Chen N; Yu T; Zhou Q
J Transl Med; 2023 Nov; 21(1):840. PubMed ID: 37993879
[TBL] [Abstract] [Full Text] [Related]
11. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
12. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
[TBL] [Abstract] [Full Text] [Related]
13. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
14. DNA methylation sites in early adulthood characterised by pubertal timing and development: a twin study.
Sehovic E; Zellers SM; Youssef MK; Heikkinen A; Kaprio J; Ollikainen M
Clin Epigenetics; 2023 Nov; 15(1):181. PubMed ID: 37950287
[TBL] [Abstract] [Full Text] [Related]
15. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer.
Oshima M; Takayama KI; Yamada Y; Kimura N; Kume H; Fujimura T; Inoue S
Sci Rep; 2023 Nov; 13(1):19602. PubMed ID: 37950047
[TBL] [Abstract] [Full Text] [Related]
16. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
17. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract] [Full Text] [Related]
18. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
19. HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers.
Morozov VM; Riva A; Sarwar S; Kim WJ; Li J; Zhou L; Licht JD; Daaka Y; Ishov AM
Nucleic Acids Res; 2023 Oct; 51(19):10194-10217. PubMed ID: 37638746
[TBL] [Abstract] [Full Text] [Related]
20. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
[TBL] [Abstract] [Full Text] [Related]
[Next]
